GH Research PLC (GHRS) stock
GHRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 5, 2026Score 1/30
$18.75−0.35 (-1.83%)
Close on Nov 16, 2026Market cap $1.16BP/E –Yield –
GH Research ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
GH Research's ebitda for the twelve months ending Jun 30, 2026 was -$71.13M. For fiscal 2025 it was -$60.38M. The highest annual figure on record is -$310.00K in fiscal 2019.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$60.38M | – |
| FY2024 | Dec 31, 2024 | -$50.00M | – |
| FY2023 | Dec 31, 2023 | -$40.91M | – |
| FY2022 | Dec 31, 2022 | -$30.51M | – |
| FY2021 | Dec 31, 2021 | -$15.08M | – |
| FY2020 | Dec 31, 2020 | -$446.00K | – |
| FY2019 | Dec 31, 2019 | -$310.00K | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$19.36M | – |
| Q1 FY2026 | Mar 31, 2026 | -$18.66M | – |
| Q4 FY2025 | Dec 31, 2025 | -$16.63M | – |
| Q3 FY2025 | Sep 30, 2025 | -$16.48M | – |
| Q2 FY2025 | Jun 30, 2025 | -$14.62M | – |
| Q1 FY2025 | Mar 31, 2025 | -$12.66M | – |
| Q4 FY2024 | Dec 31, 2024 | -$12.87M | – |
| Q3 FY2024 | Sep 30, 2024 | -$12.54M | – |
| Q2 FY2024 | Jun 30, 2024 | -$13.14M | – |
| Q1 FY2024 | Mar 31, 2024 | -$11.45M | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.08M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.64M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.85M | – |
| Q1 FY2023 | Mar 31, 2023 | -$10.34M | – |
| Q4 FY2022 | Dec 31, 2022 | -$9.16M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.61M | – |
See a number that looks wrong?